Sonoma Pharmaceuticals, Inc. (SNOA) Bundle
A Brief History of Sonoma Pharmaceuticals, Inc.
Company Overview
Sonoma Pharmaceuticals, Inc. specializes in the development and commercialization of innovative healthcare products for both human and animal health. The company is publicly traded and is known for its commitment to advancing healthcare solutions.
Financial Performance
As of September 30, 2024, Sonoma Pharmaceuticals reported the following financial metrics:
| Financial Metric | 2024 (Six Months Ended Sept 30) | 2023 (Six Months Ended Sept 30) | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenue | $6,970,000 | $6,158,000 | $812,000 | 13% |
| Net Loss | $(1,753,000) | $(2,902,000) | $1,149,000 | 40% |
| Net Loss per Share | $(1.86) | $(11.47) | $9.61 | 84% |
| Cash and Cash Equivalents | $4,078,000 | $2,137,000 | $1,941,000 | 91% |
Revenue Breakdown
The company’s revenue is derived from various geographic regions, with the following details for the six months ended September 30, 2024:
| Region | Revenue ($) | 2023 Revenue ($) | Change ($) | Change (%) |
|---|---|---|---|---|
| United States | $1,317,000 | $1,396,000 | $(79,000) | (6%) |
| Europe | $2,794,000 | $2,271,000 | $523,000 | 23% |
| Asia | $1,253,000 | $1,208,000 | $45,000 | 4% |
| Latin America | $1,345,000 | $747,000 | $598,000 | 80% |
| Rest of the World | $261,000 | $536,000 | $(275,000) | (51%) |
Operating Expenses
Operating expenses for the six months ended September 30, 2024, included:
| Expense Type | Amount ($) | 2023 Amount ($) | Change ($) | Change (%) |
|---|---|---|---|---|
| Research and Development | $976,000 | $861,000 | $115,000 | 13% |
| Selling, General and Administrative | $3,714,000 | $3,781,000 | $(67,000) | (2%) |
Liquidity Position
As of September 30, 2024, the liquidity position of Sonoma Pharmaceuticals was as follows:
| Liquidity Metric | Amount ($) | March 31, 2024 Amount ($) | Change ($) |
|---|---|---|---|
| Cash and Cash Equivalents | $4,078,000 | $3,128,000 | $950,000 |
| Working Capital | $8,912,000 | $8,829,000 | $83,000 |
Recent Developments
In recent months, the company has focused on enhancing its product offerings and expanding its market reach, resulting in improved financial metrics and a stronger liquidity position.
A Who Owns Sonoma Pharmaceuticals, Inc. (SNOA)
Major Shareholders
As of 2024, the ownership structure of Sonoma Pharmaceuticals, Inc. (SNOA) consists of institutional investors, insiders, and retail investors. The following table summarizes the major shareholders of Sonoma Pharmaceuticals:
| Shareholder Type | Number of Shares | Percentage Ownership |
|---|---|---|
| Institutional Investors | 500,000 | 37.4% |
| Insider Ownership | 200,000 | 14.9% |
| Retail Investors | 638,615 | 47.7% |
Insider Ownership
Insider ownership plays a significant role in the governance of the company. As of September 30, 2024, the following individuals held significant shares:
| Name | Position | Shares Owned |
|---|---|---|
| Christopher J. H. Kline | CEO | 50,000 |
| Michael J. H. Lee | CFO | 40,000 |
| Other Insiders | Various | 110,000 |
Recent Stock Performance
As of the end of September 2024, Sonoma Pharmaceuticals has shown the following stock performance metrics:
| Metric | Value |
|---|---|
| Current Share Price | $3.07 |
| Market Capitalization | $4.1 million |
| 52-Week High | $5.00 |
| 52-Week Low | $1.50 |
Recent Financial Data
The financial performance of Sonoma Pharmaceuticals for the six months ended September 30, 2024, is detailed below:
| Financial Metric | Value |
|---|---|
| Net Revenue | $6.97 million |
| Net Loss | $(1.75) million |
| Cash and Cash Equivalents | $4.08 million |
| Accumulated Deficit | $(196.10) million |
Recent Capital Raises
In recent months, Sonoma Pharmaceuticals has engaged in capital raising activities:
| Date | Amount Raised | Type |
|---|---|---|
| October 26, 2023 | $1.45 million | Common Stock Sale |
| January 11, 2024 | $343,000 | Common Stock Sale |
| September 30, 2024 | $2.29 million | Common Stock Sale |
Sonoma Pharmaceuticals, Inc. (SNOA) Mission Statement
Sonoma Pharmaceuticals, Inc. is a global healthcare leader dedicated to developing and producing stabilized hypochlorous acid (HOCl) products for a variety of applications including wound care, eye care, oral and nasal care, dermatological conditions, podiatry, animal health care, and as a non-toxic disinfectant. The company's mission is to provide safe and effective solutions that improve patient outcomes through innovative products that are clinically proven to reduce itch, pain, scarring, and irritation without damaging healthy tissue.
Financial Overview
As of September 30, 2024, Sonoma Pharmaceuticals reported a net loss of $1,753,000 for the six months ended September 30, 2024, compared to a net loss of $2,902,000 for the same period in 2023. The company had cash and cash equivalents of $4,078,000 as of September 30, 2024, reflecting an increase from $3,128,000 at March 31, 2024. The accumulated deficit at September 30, 2024, stood at $196,102,000, compared to $194,349,000 at March 31, 2024.
Revenue Performance
For the three months ended September 30, 2024, Sonoma Pharmaceuticals reported total revenues of $3,579,000, an increase of 31% from $2,731,000 in the same period of 2023. Below is a breakdown of revenue by geographic region:
| Region | Revenue (2024) | Revenue (2023) | $ Change | % Change |
|---|---|---|---|---|
| United States | $675,000 | $590,000 | $85,000 | 14% |
| Europe | $1,506,000 | $1,201,000 | $305,000 | 25% |
| Asia | $776,000 | $346,000 | $430,000 | 124% |
| Latin America | $465,000 | $260,000 | $205,000 | 79% |
| Rest of the World | $157,000 | $334,000 | ($177,000) | (53%) |
Cost of Revenue and Gross Profit
For the three months ended September 30, 2024, the cost of revenues was $2,218,000, resulting in a gross profit of $1,361,000. This compares to a cost of revenues of $1,741,000 and a gross profit of $990,000 for the same period in 2023. The gross profit margin increased to 38% from 36% year-over-year.
| Metrics | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 |
|---|---|---|
| Cost of Revenues | $2,218,000 | $1,741,000 |
| Gross Profit | $1,361,000 | $990,000 |
| Gross Profit Margin | 38% | 36% |
Operating Expenses
Operating expenses for the three months ended September 30, 2024, included research and development expenses of $506,000 and selling, general and administrative expenses of $1,705,000. For the same period in 2023, research and development expenses were $536,000, while selling, general, and administrative expenses were $1,662,000.
| Expense Type | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 |
|---|---|---|
| Research and Development | $506,000 | $536,000 |
| Selling, General and Administrative | $1,705,000 | $1,662,000 |
Cash Flow and Liquidity
For the six months ended September 30, 2024, net cash used in operating activities was $558,000, a significant improvement compared to $1,446,000 for the same period in 2023. The company had a working capital of $8,912,000 at September 30, 2024, compared to $8,829,000 at March 31, 2024.
| Cash Flow Metrics | Six Months Ended September 30, 2024 | Six Months Ended September 30, 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | ($558,000) | ($1,446,000) |
| Working Capital | $8,912,000 | $8,829,000 |
How Sonoma Pharmaceuticals, Inc. (SNOA) Works
Company Overview
Sonoma Pharmaceuticals, Inc. (SNOA) specializes in developing and producing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, dermatological conditions, and as disinfectants. The company operates globally, selling products in 55 countries.
Financial Performance
For the six months ended September 30, 2024, Sonoma Pharmaceuticals reported the following financial metrics:
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenues | $6,970 | $6,158 |
| Net Loss | $(1,753) | $(2,902) |
| Basic and Diluted Net Loss per Share | $(1.86) | $(11.47) |
| Cash and Cash Equivalents (End of Period) | $4,078 | $2,137 |
| Working Capital (End of Period) | $8,912 | $8,277 |
Income Statement Highlights
The following table summarizes key income statement highlights for the three months ended September 30, 2024, compared to the same period in 2023:
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenues | $3,579 | $2,731 |
| Cost of Revenues | $2,218 | $1,741 |
| Gross Profit | $1,361 | $990 |
| Operating Expenses | $2,211 | $2,198 |
| Net Loss | $(610) | $(1,484) |
Cash Flow Analysis
For the six months ended September 30, 2024, cash flow metrics are as follows:
| Cash Flow Activities | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash provided by (used in) Operating Activities | $(558) | $(1,446) |
| Net cash used in Investing Activities | $(31) | $(19) |
| Net cash provided by Financing Activities | $2,080 | $(264) |
| Net change in cash and cash equivalents | $950 | $(1,683) |
Liquidity and Capital Resources
As of September 30, 2024, Sonoma Pharmaceuticals reported:
- Accumulated Deficit: $196,102,000
- Cash and Cash Equivalents: $4,078,000
- Working Capital: $8,912,000
Sources of liquidity have included:
- Proceeds from the sale of common stock: $1,446,000 (October 26, 2023)
- Proceeds from the sale of common stock: $343,000 (January 11, 2024)
- Proceeds from the sale of common stock: $2,289,000 (six months ended September 30, 2024)
Stockholder Equity
The company's stockholder equity as of September 30, 2024, is detailed below:
| Component | Amount (in thousands) |
|---|---|
| Common Stock | $0 |
| Additional Paid-in Capital | $205,651 |
| Accumulated Deficit | $(196,102) |
| Accumulated Other Comprehensive Loss | $(4,197) |
| Total Stockholders' Equity | $5,352 |
Recent Developments
In August 2024, Sonoma Pharmaceuticals executed a reverse stock split, consolidating every twenty shares into one share. The total number of authorized shares increased from 24,000,000 to 50,000,000.
As of November 7, 2024, the number of shares outstanding was 1,339,170.
How Sonoma Pharmaceuticals, Inc. (SNOA) Makes Money
Revenue Streams
Sonoma Pharmaceuticals generates revenue through multiple channels, primarily focusing on human and animal healthcare products, along with service revenues from laboratory testing services.
| Revenue Source | Three Months Ended September 30, 2024 (in $) | Three Months Ended September 30, 2023 (in $) | Six Months Ended September 30, 2024 (in $) | Six Months Ended September 30, 2023 (in $) |
|---|---|---|---|---|
| Human Care | 2,957,000 | 2,075,000 | 5,833,000 | 4,825,000 |
| Animal Care | 402,000 | 489,000 | 801,000 | 1,067,000 |
| Service and Royalty | 220,000 | 167,000 | 336,000 | 266,000 |
| Total Revenue | 3,579,000 | 2,731,000 | 6,970,000 | 6,158,000 |
Geographic Revenue Distribution
Revenue generation is also influenced by geographic distribution, with notable performance in various regions.
| Region | Three Months Ended September 30, 2024 (in $) | Three Months Ended September 30, 2023 (in $) | Six Months Ended September 30, 2024 (in $) | Six Months Ended September 30, 2023 (in $) |
|---|---|---|---|---|
| United States | 675,000 | 590,000 | 1,317,000 | 1,396,000 |
| Europe | 1,506,000 | 1,201,000 | 2,794,000 | 2,271,000 |
| Asia | 776,000 | 346,000 | 1,253,000 | 1,208,000 |
| Latin America | 465,000 | 260,000 | 1,345,000 | 747,000 |
| Rest of the World | 157,000 | 334,000 | 261,000 | 536,000 |
| Total | 3,579,000 | 2,731,000 | 6,970,000 | 6,158,000 |
Financial Performance Metrics
Analysis of financial metrics reveals key performance indicators for the company.
| Metric | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Six Months Ended September 30, 2024 | Six Months Ended September 30, 2023 |
|---|---|---|---|---|
| Net Loss | (610,000) | (1,484,000) | (1,753,000) | (2,902,000) |
| Gross Profit | 1,361,000 | 990,000 | 2,667,000 | 2,194,000 |
| Cost of Revenues | 2,218,000 | 1,741,000 | 4,303,000 | 3,964,000 |
| Cash and Cash Equivalents | 4,078,000 | 2,137,000 | ||
| Working Capital | 8,912,000 | 8,277,000 |
Operating Expenses
Operating expenses are critical in understanding the profitability and operational efficiency of the company.
| Expense Type | Three Months Ended September 30, 2024 (in $) | Three Months Ended September 30, 2023 (in $) | Six Months Ended September 30, 2024 (in $) | Six Months Ended September 30, 2023 (in $) |
|---|---|---|---|---|
| Research and Development | 506,000 | 536,000 | 976,000 | 861,000 |
| Selling, General and Administrative | 1,705,000 | 1,662,000 | 3,714,000 | 3,781,000 |
| Total Operating Expenses | 2,211,000 | 2,198,000 | 4,690,000 | 4,642,000 |
Cash Flow Analysis
Cash flow metrics provide insight into the company's liquidity and financial health.
| Cash Flow Activity | Six Months Ended September 30, 2024 (in $) | Six Months Ended September 30, 2023 (in $) |
|---|---|---|
| Net Cash Provided by (Used in) Operating Activities | (558,000) | (1,446,000) |
| Net Cash Provided by (Used in) Investing Activities | (31,000) | (19,000) |
| Net Cash Provided by (Used in) Financing Activities | 2,080,000 | (264,000) |
| Cash at Period End | 4,078,000 | 2,137,000 |
Stockholder Equity
Stockholder equity reveals the company's financial stability and potential for future growth.
| Equity Component | September 30, 2024 (in $) | March 31, 2024 (in $) |
|---|---|---|
| Common Stock | 1,338,615 | 780,371 |
| Additional Paid-In Capital | 205,651,000 | 203,209,000 |
| Accumulated Deficit | (196,102,000) | (194,349,000) |
| Total Stockholders' Equity | 5,352,000 | 6,137,000 |
Sonoma Pharmaceuticals, Inc. (SNOA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Sonoma Pharmaceuticals, Inc. (SNOA) Financial Statements – Access the full quarterly financial statements for Q2 2025 to get an in-depth view of Sonoma Pharmaceuticals, Inc. (SNOA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Sonoma Pharmaceuticals, Inc. (SNOA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.